Colon Cancer Clinical Trial
Imaging With [89Zr]Panitumumab-PET/MRI in Patients With Newly Diagnosed Colorectal Cancer
Summary
This clinical study will investigate the utility of PET imaging with [89Zr]Panitumumab for imaging of EGFR expression in newly diagnosed colon cancer patients to assess lymph node involvement. If promising, this data will be used to design larger trials.
Eligibility Criteria
Inclusion Criteria:
Be at least 19 years of age.
Diagnosis of colon cancer
Scheduled to undergo surgical resection
Exclusion Criteria:
Inability to provide informed consent
Pregnancy
Inability to lie still for the imaging study
Weight over 350 lbs., due to the scanner bore size
Contraindication for MRI study (e.g. non-removable metal implants or certain tattoos)
Inability to receive Omnipaque (iohexol) iodinated contrast
Inability to receive glucagon
Inability to receive Eovist (gadoxetate disodium) gadolinium based contrast agent
Allergy to contrast imaging agents
Finding or suspicion of distant metastases on CT
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Birmingham Alabama, 35294, United States
How clear is this clinincal trial information?